Patents & Publications

  • Induction of Heme Oxygenase I (HMOX1) by HPP-4382: A novel modulator of Bach-1 activity”; Otis Attucks, Kimberly Jasmer, Mark Hannink, Jareer Kassis, Zhenping Zhong, Suparna Gupta, Sam Victory, Mustafa Guzel, Dharma Polisetti, Robert Andrews, Adnan Mjalli, and Matthew Kostura; PLoSOne, 9, 7, (2014), p:1-12, e101044.
  • Synthesis of Azabridged Bicyclic Ring Systems by Intramolecular Sakurai Reactions“; Mustafa Guzel, Robert Smitherman, and Sezgin Kiren; Tetrahedron Letters, manuscript submitted, 2014.
  • Substituted Pyran Derivatives Useful as Antitumor Agents“; Mustafa Guzel, Devi Reddy, Rongyuan Xie, Dharma R. Polisetti, Stephen Davis, Soumya Sahoo, Hassan El Abdelloui, and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent #US 61/892,053, 2013.
  • Substituted Fused Oxazoline Derivatives Useful as Antitumor Agents“; Mustafa Guzel, Devi Reddy, Rongyuan Xie, Dharma R. Polisetti, Soumya Sahoo, Stephen Davis, Mohan Rao, Kalpathy Santhosh, and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent #US 61/892,018, 2013.
  • Characterization and application of molecular binary mixed molecular micelles of sodium10-undecenyl sulfate and sodium N-undecenyl leucinate as pseudostationary phases in micellar electrokinetic chromatography“; Cevdet Akbay, Hamid H. Ahmed, Hakan Arslan, Brittany Graham, and Mustafa Guzel; Talanta, 99, (2012), 441-449.
  • Study of chemical selectivity of binary mixed micelles of sodium 10-undecenyl sulfate and sodium N-undecenyl leucinate using linear solvation energy reletionships model“; Hamid H. Ahmed, David M. Ahlstrom, Hakan Arslan, Mustafa Guzel, and Cevdet Akbay; Journal of Chromatography A, 1236, (2012), 207-214.
  • Novel Anticancer agents for hexokinase inhibition-Substituted cyclic-3-indole derivatives”; Mustafa Guzel, Rongyuan Xie, Dharma R. Polisetti, Robert C. Andrews, Adnan M. M. Mjalli, and Stephen Davis; High Point Pharmaceuticals Inc., High Point, NC, Application No: HPP 3018.001 US; patent manuscript submitted, 2013.
  • Substituted Benzimidazole Derivatives and Methods of Use to Treat Oxidative Stress”; Mustafa Guzel, Sam Victory, Dharma R. Polisetti, Mathew Kostura, Adnan M. M. Mjalli, Otis Attucks, and Jareer Kassis; High Point Pharmaceuticals Inc., High Point, NC, Application No: HPP 3007.000 US; patent manuscript submitted, 2012.
  • Substituted Pyridine derivatives, Pharmaceutical Compositions, and Methods of Use to Treat Oxidative Stress”; Mustafa Guzel, Sam Victory, Bapu Gaddam, Dharma R. Polisetti, Mathew Kostura and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent # WO 2011/022216, (02, 24, 2011).
  • Oxadiazoanthracene Compounds, for Treatments of Diabetes”; Scott T. Yokum, Mustafa Guzel, Kalpathy C. Santhosh, Dharma R. Polisetti, Daniel P. Christen, Adnan M. Mjalli, and Stephen T. Davis; TransTech Pharma Inc., High Point, NC, , Patent # US 2011/7906507 (03, 15, 2011).
  • In Silico Ligand-Receptor Docking of Potentially Selective Butyrylcholinesterase Inhibitors Structurally Related to the Marine Natural Product Debromoflustramine B”; Miguel O. Mitchell, Robert W. Figliozzi and Mustafa Guzel;Medicinal Chemistry, Volume 6, Number 3, 2010, 141-143.
  • Substituted Pyridine derivatives, Pharmaceutical Compositions, and Methods of Use to Treat Oxidative Stress”; Mustafa Guzel, Sam Victory, Bapu Gaddam, Dharma R. Polisetti, Mathew Kostura and Adnan M. M. Mjalli; High Point Pharmaceuticals Inc., High Point, NC, Patent # US 2010/044508, (05, 08, 2010).
  • Mandelic Acid Derivatives and Preparation Thereof”; Mustafa Guzel, Scott T. Yokum, and Dharma R. Polisetti; TransTech Pharma Inc., High Point, NC, Patent # US 2010/0036150, (02,11, 2010).
  • Oxadiazoanthracene Compounds, Compositions of Oxadiazoanthracene Compounds and Methods of Treatment Using the Same”; Scott T. Yokum, Mustafa Guzel, Kalpathy C. Santhosh, Dharma R. Polisetti, Daniel P. Christen, Adnan M. Mjalli, and Stephen T. Davis; TransTech Pharma Inc., High Point, NC, , Patent # US 2010/0324033 (12, 23, 2010).
  • Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof”; Mustafa Guzel, Scott T. Yokum, Kalpathy C. Santhosh, Dharma R. Polisetti, Chris Behme, Adnan M. Mjalli, and Stephen T. Davis”; TransTech Pharma Inc., High Point, NC, Patent # WO 2010/4824 (07, 10, 2010).
  • Tricyclic Compounds as Modulators of TNF-a Synthesis”; Mustafa Guzel, Mathew Kostura, Adnan M. Mjalli, Bapu Gaddam, and Dharma R. Polisetti; TransTech Pharma Inc., High Point, NC, Patent # US 2010/0190808 (07, 29, 2010).
  • Oxadiazoanthracene Compounds, for Treatments of Diabetes”; Scott T. Yokum, Mustafa Guzel, Kalpathy C. Santhosh, Dharma R. Polisetti, Daniel P. Christen, Adnan M. Mjalli, and Stephen T. Davis; TransTech Pharma Inc., High Point, NC, , Patent # WO 2009/111700 (11, 09, 2009).
  • Aryl Carbonyl Derivatives as Therapeutic Agents-Part-II”; Kalpaty C. Santhosh, Mustafa Guzel, Dharma R. Polisetti, Adnan M. Mjalli, and Robert C. Andrews; TransTech Pharma Inc., High Point, NC, Patent # US 2009/7541373 (06, 02, 2009).
  • Tricyclic Compounds as Modulators of TNF-a Synthesis as PDE4 Inhibitors”; Mustafa Guzel, Mathew Kostura, Adnan M. Mjalli, Bapu Gaddam, and Dharma R. Polisetti; TransTech Pharma Inc., High Point, NC, Patent # WO 2009/094528, (07, 30, 2009).